Safepace 2 | Safepace 1 | p Value | |
Baseline characteristics: | |||
Age | 78 | 73.2 | <0.001 |
Gender (% female) | 61.5 | 59.4 | 0.088 |
Mean syncope events in year before the implantation | 0.35 | 5.59 | <0.0000001 |
Comorbid disease: | |||
Ischaemic heart disease (%) | 25.4 | 9.1 | <0.001 |
Hypertension (%) | 30.8 | 25.7 | 0.06 |
Diabetes (%) | 17.7 | 9.1 | 0.012 |
Medication: | |||
β Blockers (%) | 8.5 | 0.6 | <0.01 |
ACE inhibitors (%) | 16.2 | 8.0 | 0.03 |
Diuretic therapy (%) | 26.2 | 21.1 | 0.06 |
No MMSE (mini-mental state) 12-month follow-up data available for Safepace 1.